Liraglutide (Saxenda): The First GLP-1 for Weight Loss

Last Updated: March 2026

In the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg produced an average weight loss of 8.4 kg (18.5 lbs) compared to 2.8 kg (6.2 lbs) with placebo over 56 weeks—a net difference of 5.6 kg or roughly 5.8% of body weight (New England Journal of Medicine, 2015). That data earned liraglutide FDA approval in December 2014 as Saxenda, making it the first GLP-1 receptor agonist specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

A decade later, liraglutide sits in an awkward position. It’s been eclipsed by semaglutide (Wegovy) and tirzepatide (Zepbound), which deliver two to three times the weight loss. But the 2026 FDA approval of generic liraglutide injection from Teva Pharmaceuticals has revived interest in this first-generation option as a potential budget-friendly gateway to GLP-1 therapy.

How Liraglutide Works

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to native human GLP-1. The drug was originally developed and approved at lower doses (1.2 mg and 1.8 mg) as Victoza for type 2 diabetes in 2010. The weight loss formulation, Saxenda, uses a higher 3.0 mg daily dose.

The mechanism is straightforward. GLP-1 receptor activation in the hypothalamus reduces appetite and food intake. It slows gastric emptying, which extends satiety after meals. In pancreatic beta cells, it enhances glucose-dependent insulin secretion—the reason GLP-1s were diabetes drugs first.

According to the FDA prescribing information, liraglutide has a half-life of approximately 13 hours, necessitating once-daily subcutaneous injection. That’s the critical difference from newer options. Semaglutide’s half-life exceeds 165 hours, enabling weekly dosing. Tirzepatide sits at roughly 5 days.

The Clinical Evidence

SCALE Obesity and Prediabetes

The pivotal trial enrolled 3,731 adults without diabetes across 27 countries. Participants had a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with dyslipidemia or hypertension. Average baseline weight was 106 kg (233 lbs).

After 56 weeks, 63.2% of liraglutide patients lost at least 5% of body weight compared to 27.1% on placebo. Weight loss of 10% or more occurred in 33.1% vs 10.6%. The mean difference in weight change was -5.6 kg.

The trial protocol included a 500 kcal/day deficit diet and at least 150 minutes of weekly physical activity—standard lifestyle intervention. “At week 56, more participants in the liraglutide group than in the placebo group had lost at least 5% of their body weight (63.2% vs. 27.1%, P<0.001),” the authors wrote in NEJM.

SCALE Diabetes

A separate trial enrolled 846 adults with type 2 diabetes and obesity. Liraglutide 3.0 mg produced 6.0% weight loss vs 2.0% for placebo over 56 weeks—a smaller effect than in the non-diabetic population but still statistically significant.

This reflects a consistent pattern across GLP-1 weight loss medications: people with diabetes lose less weight than those without diabetes, likely due to underlying metabolic differences and concurrent diabetes medications that may promote weight gain.

Maintenance Data

The SCALE Maintenance trial tested liraglutide in people who had already lost at least 5% of body weight through a low-calorie diet run-in period. After randomization, liraglutide patients lost an additional 6.2% vs 0.2% weight regain with placebo over 56 weeks.

This addresses a critical question: can GLP-1s help maintain weight loss after initial reduction? The answer appears to be yes, though long-term data beyond one year remains limited for liraglutide specifically.

How It Compares to Newer GLP-1s

The weight loss hierarchy is clear. In the STEP 1 trial, semaglutide 2.4 mg weekly produced 14.9% weight loss vs 2.4% for placebo at 68 weeks. Tirzepatide 15 mg weekly delivered 20.9% weight loss vs 3.1% for placebo in the SURMOUNT-1 trial at 72 weeks.

Liraglutide’s 5.8% net effect looks modest by comparison. But context matters. When liraglutide earned FDA approval in 2014, the only other long-term weight loss medications were orlistat (modest efficacy, gastrointestinal side effects), phentermine-topiramate (effective but limited by cardiovascular and psychiatric concerns), and naltrexone-bupropion (moderate efficacy).

Liraglutide represented a meaningful advance. It just happened to launch a decade before the category exploded.

Side Effects and Tolerability

Nausea is the dominant side effect. In SCALE Obesity and Prediabetes, 39.3% of liraglutide patients reported nausea vs 13.8% on placebo. Diarrhea occurred in 20.9% vs 9.9%. Vomiting in 15.7% vs 3.5%.

The FDA label includes a boxed warning for thyroid C-cell tumors, based on rodent studies showing increased incidence of medullary thyroid carcinoma. Human relevance remains uncertain, but liraglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other warnings include pancreatitis (though causation is debated), gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas.

Discontinuation rates in SCALE trials hovered around 25% to 30%, primarily due to gastrointestinal side effects. The dose escalation schedule—starting at 0.6 mg and increasing by 0.6 mg weekly to 3.0 mg—aims to improve tolerability, but daily injections test adherence.

Cost and Access

Brand-name Saxenda lists at approximately $1,349 per month without insurance. Insurance coverage varies widely. Many commercial plans cover GLP-1s for diabetes but exclude weight loss indications. Medicare Part D explicitly cannot cover weight loss medications per the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The 2026 generic approval changes the equation. Teva has not disclosed generic liraglutide pricing, but typical generic launches start at 50% to 80% of brand cost before competition drives further reductions.

For patients without insurance coverage for semaglutide or tirzepatide—both still on patent and priced near $1,000 to $1,349 monthly—generic liraglutide may provide an accessible alternative despite lower efficacy.

Who Might Choose Liraglutide

The patient profile for liraglutide in 2026 is specific:

Budget-constrained patients without insurance coverage for newer GLP-1s. If generic liraglutide costs $400 to $700 per month, it becomes the most affordable GLP-1 option for weight loss.

Patients seeking modest weight loss. Someone targeting 5% to 8% weight reduction for health benefits rather than maximum weight loss might accept daily injections for lower cost.

Patients with prior GLP-1 experience. People who have used liraglutide for diabetes (Victoza) and tolerated it well may prefer familiar territory.

Patients ineligible for higher-dose GLP-1s. Certain contraindications or tolerability issues might make lower-potency liraglutide preferable.

Conversely, patients seeking maximum weight loss, preferring weekly dosing, or with insurance coverage for semaglutide or tirzepatide will likely opt for newer agents.

The Broader Picture

Liraglutide’s story illustrates how quickly obesity pharmacotherapy has evolved. A medication that was groundbreaking in 2014 now serves as a budget alternative. That’s not a criticism—it’s pharmaceutical innovation functioning as intended.

Research continues on whether sequential therapy makes sense. Could patients start with liraglutide, lose initial weight at lower cost, then transition to semaglutide or tirzepatide for additional reduction? No published trials address this directly, but real-world practice may generate data.

The obesity medicine community has also learned from liraglutide’s limitations. The inconvenience of daily injections and gastrointestinal side effects drove development of longer-acting formulations. Semaglutide’s weekly dosing emerged partly from recognition that adherence matters as much as pharmacology.

Practical Considerations

Liraglutide requires refrigeration before first use, then can be stored at room temperature (below 86°F) for 30 days after opening. The pen delivers doses in 0.6 mg increments up to 3.0 mg.

Injection sites include abdomen, thigh, or upper arm. Rotating sites reduces lipohypertrophy risk. The medication should be taken at approximately the same time each day, though timing relative to meals doesn’t significantly affect absorption.

Patients on liraglutide should undergo monitoring for heart rate increases (average elevation of 2 to 3 beats per minute in trials) and periodic assessment for depression or suicidal thoughts, as reported in some post-marketing surveillance.

Looking Forward

The GLP-1 weight loss landscape will continue shifting. Oral semaglutide at higher doses is in development. Combination therapies pairing GLP-1s with other mechanisms are in trials. Gene therapies and alternative delivery systems are in early research.

Liraglutide’s role may shrink as patents expire on newer agents and competition drives down costs across the category. But for now, it occupies a specific niche: the most affordable GLP-1 option for weight loss, with a decade of real-world safety data and proven—if modest—efficacy.

The 5.8% average weight loss liraglutide delivers is clinically meaningful. Studies consistently show that 5% to 10% weight reduction improves blood pressure, lipids, glycemic control, and reduces progression to type 2 diabetes in people with prediabetes. Perfect is the enemy of good, especially when good costs half as much.

Sources

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373:11-22. https://www.nejm.org/doi/full/10.1056/NEJMoa1411892

2. U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information. December 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf

3. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2015;39:187-191. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674659/

4. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. https://jamanetwork.com/journals/jama/fullarticle/2654047

5. FDA Approves Generic Version of Liraglutide Injection, a GLP-1 for Weight Loss. Pharmacy Times. 2026. https://www.pharmacytimes.com/view/fda-approves-generic-version-of-liraglutide-injection-a-glp-1-for-weight-loss